Lineage Cell Therapeutics, Inc. (LCTX)Healthcare | Biotechnology | Carlsbad, United States | NYSE American
1.11 USD
-0.05
(-4.310%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.11 |
Hot Take ↕ | Aug. 22, 2026, 2:53 a.m. EDT
The investment case for Lineage Cell Therapeutics is defined by a stark disconnect between its deteriorating business fundamentals and aggressive speculative positioning. Fundamentally, the company is in a severe decline; revenue has contracted by nearly 62% year-over-year, profitability is nonexistent with gross margins in negative territory, and the stock has lost more than half its value over the last nine years. The balance sheet shows massive free cash outflows, and despite a 'strong buy' analyst recommendation, the consensus target price implies a recovery that the current operational metrics do not yet support. However, the short-term outlook is driven entirely by options speculation rather than operational improvement. The options chain reveals a heavy buildup of call open interest at $1.50 and $2.00 strikes, creating a potential 'wall' of support that could trigger a mechanical bounce if the price approaches these levels. This speculative fervor is evident in the recent price action, which has been trading near the 52-week low, yet traders are betting on a reversal. Given the lack of dividend support, the negative earnings trajectory, and the reliance on a speculative options squeeze rather than sustainable business growth, the long-term outlook remains deeply bearish. The stock is currently a high-risk vehicle for traders hoping for a catalyst, but a poor investment for capital preservation. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.090799 |
| AutoETS | 0.091970 |
| MSTL | 0.095548 |
| AutoTheta | 0.114939 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 2.78 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.073 |
| Excess Kurtosis | -0.77 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2003-12-14 |
| Debt to Equity Ratio | 3.845 |
| Revenue per Share | 0.054 |
| Market Cap | 280,727,264 |
| Forward P/E | -10.88 |
| Beta | 1.55 |
| Profit Margins | -246.58% |
| Website | https://www.lineagecell.com |
As of Aug. 22, 2026, 2:53 a.m. EDT: Speculators are positioning for a significant upside move, evidenced by heavy open interest concentration at $1.50 and $2.00 strikes across multiple expirations. Call volume significantly exceeds put volume, particularly in the longer-dated March 2027 contracts where new call flow is appearing. Conversely, put activity is negligible, with almost no open interest beyond the immediate term, suggesting a lack of hedging against a downside crash and a speculative bias toward a rally.
| Date | Dividend | Yield % |
|---|---|---|
| 2003-12-15 | 0.064568 | 5.555594 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.090163946 |
| Address1 | 2,173 Salk Avenue |
| Address2 | Suite 200 |
| All Time High | 21.791555 |
| All Time Low | 0.080709 |
| Ask | 1.12 |
| Ask Size | 6,000 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 904,700 |
| Average Daily Volume3 Month | 1,353,749 |
| Average Volume | 1,353,749 |
| Average Volume10Days | 904,700 |
| Beta | 1.547 |
| Bid | 1.11 |
| Bid Size | 127,100 |
| Board Risk | 3 |
| Book Value | 0.241 |
| City | Carlsbad |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.11 |
| Current Ratio | 6.608 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.1762 |
| Day Low | 1.11 |
| Debt To Equity | 3.845 |
| Display Name | Lineage Cell Therapeutics |
| Earnings Call Timestamp End | 1,786,046,400 |
| Earnings Call Timestamp Start | 1,786,046,400 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -26,111,000 |
| Ebitda Margins | -1.9958 |
| Enterprise To Ebitda | -8.85 |
| Enterprise To Revenue | 17.663 |
| Enterprise Value | 231,079,280 |
| Eps Current Year | -0.062 |
| Eps Forward | -0.102 |
| Eps Trailing Twelve Months | -0.19 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.164 |
| Fifty Day Average Change | -0.05400002 |
| Fifty Day Average Change Percent | -0.04639177 |
| Fifty Two Week Change Percent | -9.016395 |
| Fifty Two Week High | 2.09 |
| Fifty Two Week High Change | -0.9799999 |
| Fifty Two Week High Change Percent | -0.4688995 |
| Fifty Two Week Low | 1.0 |
| Fifty Two Week Low Change | 0.110000014 |
| Fifty Two Week Low Change Percent | 0.110000014 |
| Fifty Two Week Range | 1.0 - 2.09 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 699,805,800,000 |
| Float Shares | 190,889,496 |
| Forward Eps | -0.102 |
| Forward P E | -10.882353 |
| Free Cashflow | -14,774,250 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 72 |
| Fullday Change | -0.05 |
| Fullday Change Percent | -4.31034 |
| Fullday Price | 1.11 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -0.57365 |
| Gross Profits | -7,505,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.048600003 |
| Held Percent Institutions | 0.48186 |
| Implied Shares Outstanding | 252,907,464 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,071,446,400 |
| Last Dividend Value | 0.064568 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 878,256,000 |
| Last Split Factor | 3:1 |
| Long Business Summary | Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. |
| Long Name | Lineage Cell Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 280,727,264 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_25622 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -32,260,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 293,372,658 |
| Number Of Analyst Opinions | 6 |
| Open | 1.16 |
| Operating Cashflow | -23,816,000 |
| Operating Margins | -8.34705 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Peg Ratio | 10.64 |
| Phone | 442 287 8990 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.11 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 1.16 |
| Price Eps Current Year | -17.903227 |
| Price Hint | 4 |
| Price To Book | 4.605809 |
| Price To Sales Trailing12 Months | 21.457407 |
| Profit Margins | -2.4658 |
| Quick Ratio | 6.46 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.05 |
| Regular Market Change Percent | -4.31034 |
| Regular Market Day High | 1.1762 |
| Regular Market Day Low | 1.11 |
| Regular Market Day Range | 1.11 - 1.1762 |
| Regular Market Open | 1.16 |
| Regular Market Previous Close | 1.16 |
| Regular Market Price | 1.11 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 587,283 |
| Return On Assets | -0.17035 |
| Return On Equity | -0.6006 |
| Revenue Growth | -0.613 |
| Revenue Per Share | 0.054 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 252,907,464 |
| Shares Percent Shares Out | 0.111999996 |
| Shares Short | 28,331,489 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 29,867,928 |
| Short Name | Lineage Cell Therapeutics, Inc. |
| Short Percent Of Float | 0.1858 |
| Short Ratio | 29.58 |
| Source Interval | 15 |
| State | CA |
| Symbol | LCTX |
| Target High Price | 9.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 5.5 |
| Target Median Price | 4.5 |
| Total Cash | 50,829,000 |
| Total Cash Per Share | 0.201 |
| Total Debt | 2,299,000 |
| Total Revenue | 13,083,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.48455 |
| Two Hundred Day Average Change | -0.37454998 |
| Two Hundred Day Average Change Percent | -0.25229865 |
| Type Disp | Equity |
| Volume | 587,283 |
| Website | https://www.lineagecell.com |
| Zip | 92,008 |